Hologic Reports Organizational Changes to Diagnostics Unit

Hologic, Inc. ("Hologic" or "theCompany") (NASDAQ: HOLX), a leading developer, manufacturer and supplier ofpremium diagnostics products, medical imaging systems and surgical productsdedicated to serving the healthcare needs of women, today announcedorganizational changes to its Diagnostics segment. Based upon the successful progress achieved in the ongoing integration ofGen-Probe Incorporated ("Gen-Probe"), which is proceeding ahead of schedule,and the solid foundation of the Diagnostics segment, Hologic has acceleratedthe timing of several planned organizational changes. In conjunction with theCompany's accelerated execution, Carl Hull will be retiring from his role asSenior Vice President and General Manager of Diagnostics. Mr. Hull, who servedas Chairman, President and Chief Executive Officer of Gen-Probe until thatcompany was acquired by Hologic in August 2012, will continue with the Companyas a consultant up to mid-August 2013."We are confident that now is the right time to transition our team and we aregrateful for the deep bench of talent within the Hologic and legacy Gen-Probeorganizations who are well positioned to successfully assume greater levels ofresponsibility as we continue to grow," said Rob Cascella, President and ChiefExecutive Officer of Hologic. "Carl has been instrumental in the ongoing andsuccessful integration of Gen-Probe into Hologic that has supported our rapidprogress. We have benefitted from his experience, deep knowledge of theindustry and valuable relationships and we thank Carl for his leadership andcommitment. We look forward to his continued contributions throughout 2013,including his support in facilitating a seamless leadership transition.""We have a well-defined strategic path forward to grow the diagnosticsbusinesses globally, drive innovation and expand our technology offerings,"said Mr. Hull. "I look forward to working with Rob and the rest of the team toensure that we capture the benefits of the Gen-Probe transaction for all ofour stakeholders. We are very excited about our future and are confident thattoday, Hologic is well positioned to build upon its leadership role indiagnostics as it continues to meet the expanding needs of its customers."As part of the organizational changes, Rohan Hastie, formerly a vice presidentand general manager within the Women's Health group of the Company'sDiagnostics segment, has been appointed Senior Vice President and GroupGeneral Manager - Diagnostics, which now includes overseeing the segment'sWomen's Health and Virology businesses, as well as the U.S. Diagnostics salesteam. In addition, Eric Tardif, Senior Vice President of Commercial Operations- Diagnostics, will assume the role of Senior Vice President of CorporateStrategy, partnering with Mr. Cascella and the business leaders to furthershape Hologic's long-range goals.On Track to Achieve Over $40 Million in First-Year Cost Synergies:Hologic has made significant progress in integrating Gen-Probe into itsexisting Diagnostics segment. The Company remains on track to realize over $40million in cost synergies by the end of the first year following theacquisition and an additional $35 million in cost synergies by the end of thethird year. In addition, Hologic is continuing to drive revenue synergies byutilizing its global sales and marketing presence to capitalize oncross-selling opportunities to leverage its expanded molecular diagnosticsproduct portfolio.